Conclusions To summarize, this secondary analysis of a randomized clinical trial examined changes in site-specific BMD during diet-induced weight loss followed by a 1-year intervention with liraglutide (3.0 mg/day), exercise, or their combination, compared to placebo
J Physiol Paris 93:479485 Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, Klicek R, Radic B, Keller N, Sipos K et al (2006) Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia)
Every drop reflects a commitment to potency and purity
60, 695704 (2011). Shahin AY, Hassanin IM, Ismail AM, Kruessel JS, Hirchenhain J
MD, MBA, MSCP3,4
While semaglutide and tirzepatide are currently FDAapproved options within this category, additional peptide therapies such as retatrutide are in advanced clinical trials